

Quarterly report

Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2025

Monica M Lahra, Siobhan M Hurley and Tiffany R Hogan for the
National Neisseria Network

The reference laboratories of the Australian National Neisseria Network report data on invasive meningococcal disease (IMD) confirmed by culture and/or molecular techniques for the Australian Meningococcal Surveillance Programme (AMSP). Culture-positive cases and molecular-based diagnoses are defined as IMD by the Communicable Diseases Network Australia (CDNA) National Guidelines for Public Health Units.¹ Data contained in the quarterly reports are restricted to a description of the number of cases by jurisdiction and serogroup, when known. The content of the quarterly reports was expanded in 2024 to include antimicrobial resistance (AMR) data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. IMD AMR data was previously only reported annually in the AMSP Annual Report, which has its own programme-specific quality assurance processes. Some minor corrections to data in Table 1 may be made in subsequent reports if additional data are received.

In Australia, there were 91 notifications of IMD between 1 January and 30 September 2025, lower than in the same period in 2024 (Table 1) and a 43.8% reduction (c.f. 162 IMD notifications) from the corresponding period in 2019 (prior to the SARS-CoV-2 pandemic).² In 2025 year-to-date (ytd), 86/91 of the national IMD notifications (94.5%) had the serogroup determined at the time of reporting. Notably, *N. meningitidis* serogroup B (MenB) IMD continued in the majority, accounting for 81.4% of disease notifications (70/86) ytd, increased from the first quarter of 2025 (72.0%).³ In contrast, between 2019 and 2021, the proportion of IMD attributable to MenB was 50.0–62.1%.⁴ IMD notifications in 2025 attributable to MenY and MenW were 9.3% (8/86) and 7.0% (6/86) ytd respectively, and no additional MenA or MenC IMD were reported in the third quarter of 2025 (Table 1).

Among 61 culture-confirmed IMD cases tested ytd, four were identified as penicillin resistant: one each from Queensland (quarter three); Northern Territory (quarter three); Victoria (quarter two); and Western Australia (quarter one). Of these, one isolate was classified as MenW (Queensland), while the remaining three were MenB. All 61 IMD isolates were susceptible to ceftriaxone and no resistance was detected to ciprofloxacin and rifampicin. A full analysis of laboratory-confirmed cases of IMD in each calendar year is contained in the AMSP annual report published in *Communicable Diseases Intelligence*.

Table 1: Number of laboratory confirmations of invasive meningococcal disease, Australia, 1 July to 30 September 2025, by serogroup and state or territory

| Jurisdiction | Year | Serogroup | | | | | | | | | | | | | |
|------------------------------|-------------|-----------|------------------|-----------|-----------|----------|----------|----------|----------|----------|-----------|-----------------|----------|-----------|------------|
| | | A | | B | | C | | W | | Y | | ND ^a | | All | |
| | | Q3 | ytd ^b | Q3 | ytd | Q3 | ytd | Q3 | ytd | Q3 | ytd | Q3 | ytd | Q3 | ytd |
| Australian Capital Territory | 2025 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| New South Wales | 2025 | 0 | 0 | 6 | 17 | 0 | 1 | 0 | 3 | 1 | 5 | 1 | 2 | 8 | 28 |
| | 2024 | 0 | 0 | 5 | 16 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 6 | 17 |
| Northern Territory | 2025 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| | 2024 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Queensland | 2025 | 0 | 0 | 2 | 16 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 4 | 19 |
| | 2024 | 0 | 0 | 15 | 27 | 1 | 1 | 0 | 0 | 1 | 2 | 2 | 3 | 19 | 33 |
| South Australia | 2025 | 0 | 0 | 4 | 8 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 5 | 9 |
| | 2024 | 0 | 0 | 9 | 19 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 11 | 22 |
| Tasmania | 2025 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| | 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Victoria | 2025 | 0 | 1 | 7 | 14 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 8 | 18 |
| | 2024 | 0 | 0 | 5 | 11 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 1 | 6 | 16 |
| Western Australia | 2025 | 0 | 0 | 4 | 11 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 5 | 13 |
| | 2024 | 0 | 0 | 5 | 8 | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 0 | 7 | 12 |
| Australia | 2025 | 0 | 1 | 25 | 70 | 0 | 1 | 2 | 6 | 4 | 8 | 1 | 5 | 32 | 91 |
| | 2024 | 0 | 0 | 40 | 83 | 1 | 1 | 0 | 2 | 7 | 12 | 2 | 4 | 50 | 102 |

a ND: not determined at time of report.

b ytd: year-to-date, data from 1 January to 30 September 2025.

Author details

Monica M Lahra^{1,2}

Siobhan M Hurley¹

Tiffany R Hogan¹

1. NSW Health Pathology, World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia
2. School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Australia

Corresponding author

Professor Monica M Lahra

The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia

Telephone: +61 2 9382 3678

Facsimile: +61 2 9382 3720

Email: monica.lahra@health.nsw.gov.au

References

1. Australian Centre for Disease Control (Australian CDC), Communicable Diseases Network Australia (CDNA). *Invasive Meningococcal Disease: CDNA National Guidelines for Public Health Units*. Canberra: Australian CDC; 4 July 2017. Available from: <https://www.cdc.gov.au/resources/publications/invasive-meningococcal-disease-cdna-national-guidelines-public-health-units>.
2. Lahra MM, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2019. *Commun Dis Intell (2018)*. 2020;44. doi: <https://doi.org/10.33321/cdi.2020.44.62>.
3. Lahra MM, Hogan TR. Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2025. *Commun Dis Intell (2018)*. 2025;49. doi: <https://doi.org/10.33321/cdi.2025.49.045>.
4. Lahra MM, George RCR, van Hal SJ, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2022. *Commun Dis Intell (2018)*. 2023;47. doi: <https://doi.org/10.33321/cdi.2023.47.44>.



Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Australian Centre for Disease Control.

The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia and the near region.

Editor

Dr Elise Firman

Deputy Editor

Simon Petrie

Design and Production

Lisa Thompson

Editorial Advisory Board

David Durrheim, Mark Ferson, Clare Huppertz, John Kaldor, Martyn Kirk and Meru Sheel

Submit an Article

Submit your next communicable disease related article to CDI for consideration.

Guidelines for authors and details on how to submit your publication is available on our website, or by email to the CDI Editor.

Contact us

Communicable Diseases Intelligence (CDI)
Australian Centre for Disease Control
GPO Box 798, Canberra ACT 2601

Website: cdc.gov.au/cdi

Email: cdi.editor@cdc.gov.au

© 2026 Commonwealth of Australia as represented by the Australian Centre for Disease Control

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence

This publication is licensed under a Creative Commons Attribution-Non-Commercial-NoDerivatives 4.0 International Licence (Licence). You must read and understand the Licence before using any material from this publication.

Restrictions

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

- the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found on the Department of Prime Minister and Cabinet website);
- any logos (including the Australian Centre for Disease Control's logo) and trademarks;
- any photographs and images;
- any signatures; and
- any material belonging to third parties.

Disclaimer

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Australian Government or the Australian Centre for Disease Control. Data may be subject to revision.

Enquiries

Enquiries regarding any other use of this publication should be addressed to the CDI Editor.